FY2025 · ended Dec 31, 2025 · Revenue $146.59M, +24.6% YoY · Filed Feb 26, 2026
Cronos Group Inc. (CRON) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $146.6 million and a net loss of $9.4 million. Free cash flow was $149,000. As of Sep 30, 2026 it held $741.2 million in cash and investments and $1.2 million in total debt.
Revenue (TTM)
$206.20M
+55.8% vs year-ago TTM
Net income (TTM)
$57.83M
+60.2% vs year-ago TTM
Operating cash flow (TTM)
$81.08M
+272.8% vs year-ago TTM
Free cash flow (TTM)
$65.38M
+1317.4% vs year-ago TTM
EPS (TTM)
$0.15
+64.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
379.05M
-0.9% vs prior year
Net cash
$739.96M
as of Sep 30, 2026
Operating margin
3.4%
FY 2026
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- CRON (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Stayner, Ontario, Canada
- SEC filer status
- Accelerated filer
- SEC CIK
- 1656472
- Former names
- PharmaCan Capital Corp. (until May 27, 2016)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
- Aurora Cannabis Inc ACB
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $146.6M | $117.6M | $87.2M | $86.7M | $64.6M |
| Operating income | -$17.4M | -$76.5M | -$84.8M | -$111.4M | -$292.0M |
| Net income | -$9.4M | $41.1M | -$74.0M | -$168.7M | -$396.1M |
| Diluted EPS | -$0.02 | $0.11 | -$0.19 | — | -$1.07 |
| Operating cash flow | $25.9M | $18.8M | -$42.8M | -$88.9M | -$153.6M |
| Free cash flow | $149,000 | $6.4M | -$45.3M | -$92.4M | -$164.8M |
| Total assets | $1.2B | $1.2B | $1.1B | $1.2B | $1.4B |
| Total liabilities | $54.2M | $55.3M | $44.1M | $72.0M | $63.5M |
| Stockholders' equity | $1.1B | $1.1B | $1.1B | $1.1B | $1.3B |
| Cash and investments | $831.8M | $858.8M | $861.5M | $877.7M | $1.0B |
| Total debt | $1.5M | $2.0M | $2.6M | $3.9M | $9.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Regulation FD disclosure
|
Oct 15, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 11, 2026 | Sep 8, 2026 |
| 8-K/A |
Amended current report
Shareholder vote results
|
Aug 7, 2026 | Jun 18, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
All 501 Cronos Group Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.